Marker Therapeutics Inc (MRKR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($18.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MRKR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Marker Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Marker Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Marker Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marker Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chai Watana Tannery Group Public Company Limited
BK:CWT
|
0.008x |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
-0.021x |
|
Deltamac Taiwan Co Ltd
TWO:6144
|
0.006x |
|
NORTHERN FREEGOLD
F:8N6
|
-0.086x |
|
Hands Corporation Ltd
KO:143210
|
0.069x |
|
Century Extrusions Limited
NSE:CENTEXT
|
0.095x |
|
Sun-Sea Construction
TWO:5516
|
0.779x |
|
AIRA Factoring Public Company Limited
BK:AF
|
-0.265x |
Annual Cash Flow Conversion Efficiency for Marker Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Marker Therapeutics Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see MRKR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $18.56 Million | $-10.91 Million | -0.588x | +49.75% |
| 2023-12-31 | $14.05 Million | $-16.44 Million | -1.170x | +14.98% |
| 2022-12-31 | $19.60 Million | $-26.97 Million | -1.376x | -121.87% |
| 2021-12-31 | $43.99 Million | $-27.28 Million | -0.620x | +15.35% |
| 2020-12-31 | $27.34 Million | $-20.03 Million | -0.733x | -76.66% |
| 2019-12-31 | $44.09 Million | $-18.28 Million | -0.415x | -69.97% |
| 2018-12-31 | $59.34 Million | $-14.48 Million | -0.244x | +89.42% |
| 2017-12-31 | $3.66 Million | $-8.44 Million | -2.307x | -119.17% |
| 2016-12-31 | $6.18 Million | $-6.51 Million | -1.053x | -617.66% |
| 2015-12-31 | $-21.36 Million | $-4.34 Million | 0.203x | -90.48% |
| 2014-12-31 | $-1.02 Million | $-2.19 Million | 2.137x | +2597.17% |
| 2013-12-31 | $-8.77 Million | $-694.58K | 0.079x | -71.32% |
| 2012-12-31 | $-5.67 Million | $-1.57 Million | 0.276x | -27.04% |
| 2011-12-31 | $-3.46 Million | $-1.31 Million | 0.379x | +33.91% |
| 2010-12-31 | $-3.27 Million | $-925.04K | 0.283x | -84.14% |
| 2009-12-31 | $-629.39K | $-1.12 Million | 1.782x | +654.23% |
| 2008-12-31 | $-3.02 Million | $-714.42K | 0.236x | -67.71% |
| 2007-12-31 | $-1.67 Million | $-1.23 Million | 0.732x | +85.14% |
| 2006-12-31 | $-3.00 Million | $-1.19 Million | 0.395x | -24.67% |
| 2005-12-31 | $-2.22 Million | $-1.16 Million | 0.525x | +5.38% |
| 2004-12-31 | $-2.44 Million | $-1.21 Million | 0.498x | -87.63% |
| 2003-12-31 | $-643.75K | $-2.59 Million | 4.026x | +233.30% |
| 2002-12-31 | $465.83K | $-1.41 Million | -3.020x | -292.90% |
| 2000-12-31 | $-561.95K | $-879.74K | 1.566x | -72.84% |
| 1999-12-31 | $-141.42K | $-815.18K | 5.764x | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-assoc… Read more